A Harvard-Affiliated Pilot Study on PEMF Technology and Sleep

Reframed from: Pavlova MK, Latreille V, Puri N, Johnsen J, Batool-Anwar S, Javaheri S, Mathew PG (2019). "Novel non-pharmacological insomnia treatment – a pilot study." Nature and Science of Sleep, 11:189–195. DOI: 10.2147/NSS.S198944

Pilot study from Harvard Medical School and Brigham and Women's Hospital

Researchers in the Department of Neurology and Department of Medicine at Harvard Medical School, Brigham and Women’s Hospital (Boston, MA) conducted a small pilot study examining the underlying PEMF technology’s effect on subjective sleep measures.

Study design

This was a single-arm, open-label pilot study — there was no placebo device, no control group, and no blinding. Twenty adults with chronic insomnia, diagnosed under ICSD-3 criteria and confirmed by a board-certified sleep medicine physician, were enrolled; 17 completed the full protocol, including pre- and post-treatment EEG. Participants held the device (BioBoosti) in each hand for six 8-minute cycles nightly for two weeks, and outcomes were assessed using standardized sleep questionnaires, sleep logs, wrist actigraphy, and ambulatory EEG. This was a clinical research population, not a general consumer group: 55% had already failed more than one hypnotic medication, and several had comorbid sleep disorders under treatment. Findings should not be extrapolated beyond the group studied. Because there was no comparison group, the study’s own authors describe the findings as hypothesis-generating rather than conclusive, and call for larger, placebo-controlled studies to establish efficacy.

What researchers observed

P-values reflect pre-to-post (within-subject) comparisons in a single-arm study with no control group. Because there was no placebo arm, these changes cannot be attributed to the device alone and may reflect other factors, including placebo response or expectation effects. No significant side effects were reported.

Why it's worth noting

Subjective sleep-quality and insomnia-severity scores improved over the two-week period — as self-reported patterns in a clinical study population, not as evidence that the device treats any condition. Objective measures told a more mixed story. Actigraphy and EEG changes were mostly small and not statistically significant; some moved favorably (time awake after sleep onset), while others did not (sleep onset latency lengthened slightly, and EEG sleep-stage measures were essentially unchanged). The authors noted the study was likely underpowered to detect these changes. The study’s authors were explicit that, given the pilot design, these findings should be considered preliminary — in their own words, “the results are not conclusive of efficacy” — and they called for larger, longer-term, placebo-controlled trials before any conclusions about effectiveness can be drawn.

This study was funded by a grant from Biomobie, Inc. to Brigham and Women’s Hospital. This research focused on the underlying PEMF technology, not the current NeuroRester consumer product; the published pilot study used a hand-held Bioboosti device (Biomobie, Shanghai, China), held in the hand rather than worn — a different form factor from NeuroRester’s wearable products. This was an uncontrolled pilot study with no placebo group; the authors themselves caution that larger, placebo-controlled studies are needed to confirm these findings. Academic affiliations reflect the researchers involved and do not constitute endorsement by Harvard University, Harvard Medical School, Brigham and Women’s Hospital, or any other institution. These statements have not been evaluated by the FDA. NeuroRester is not intended to diagnose, treat, cure, or prevent any disease, including insomnia. Individual results will vary.